AKTIESPARARNA SHAREHOLDER EVENT

F.R. Martelet, M.D., CEO

15th September 2020

Forward-looking statement

IMPORTANT NOTICE

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

Oasmia – an innovation-focused specialty pharmaceutical company

Founded in 1999
HQ Uppsala, Sweden
26* employees

XR-17™ technology platform,
allowing micelle formulations of APIs, to be soluble in water – broad applications in oncology, human and animal health

Lead product Apealea®
approved in EU/EEA for advanced ovarian cancer, partner Elevar in discussions with FDA; global commercial deal worth up to $698m + royalties

NASDAQ Stockholm 2010
Market Cap approx. SEK 2,2 B

R&D-certified Production Facility and R&D, in Uppsala, Sweden

New CEO in place since March 2020

*By end of Q1 2021

Building a sustainable, profitable specialty pharma company

MEETING UNMET MEDICAL NEED

IMPROVING SOLUBILITY & SIDE EFFECT PROFILS OF ESTABLISHED & NOVEL CANCER DRUGS

INCREASING R&D EFFICIENCY

APEALEA® APPROVED IN EUROPE

LEAD PRODUCT LAUNCHED FOR ADVANCED OVARIAN CANCER

A GLOBAL PARTNERSHIP

WORTH UP TO $678 MILLION PLUS ROYALTIES

A GROWING PIPELINE

UNDERPINNED BY STRONG IP PROTECTION

POSITIONED FOR M&A, IN/OUT-LICENSING

PROVEN DEVELOPMENT, REGULATORY AND BD SKILLS + SOLID CASH POSITION

NEW MANAGEMENT & STRATEGY

FOCUSING RESOURCES TO BUILD A SUSTAINABLE, PROFITABLE BUSINESS

The new team leading Oasmia's transformation

FRANCOIS MARTELET, M.D., Master's Degree Business
Chief Executive Officer

Previous experience:
CEO in Biotechnology/ BioPharma in UK, DNK, US and senior executive global roles at Novartis Oncology, Merck & Co., Inc with large P&L responsibility

FREDRIK JÄRRSTEN*
Chief Finance Officer

ELIN TRAMPE,
Chief Technical Officer

REINHARD KOENIG, M.D.
Acting Chief Medical Officer

PETER SELIN*
Chief Business Officer

ANDERS HÄRFSTRAND, M.D., PhD.
Non-executive Chairman

Previous experience: Experienced Pharma BoD, M&A experience, former executive positions in Pfizer, Pharmacia. Pharmacia & Upjohn

HEGE HELLSTRÖM, B.A.
Board Member

PETER ZONABEND, LL.M, EMLE
Board Member

BIRGIT STATTIN NORINDER, MSc.
Board Member

*Start date TBC

Meeting the challenges of poor drug solubility

POOR API[1] SOLUBILITY	c.40% OF APPROVED DRUGS AFFECTED[2]	A FACTOR IN SERIOUS ADVERSE EVENTS (SAEs)
MAJOR CHALLENGE FOR DRUG DEVELOPMENT CRITICAL TO DRUG BIOAVILABILITY	70-90% OF PIPELINE DRUGS CLASSED AS POORLY SOLUBLE[2] LEADING CAUSE OF PROJECT TERMINATION	SOLUBILITY ENHANCERS CAN CAUSE SAEs AND / OR REQUIRE USE OF FURTHER DRUGS AN ACCEPTED TRADE OFF IN CANCER THERAPY

$180 bn SPENT ON PHARMA R&D EVERY YEAR [3]

69% OF DRUGS FAIL DUE TO LOW SOLUBILITY [3]

1) API = Active Pharmaceutical Ingredient - the ingredient in a pharmaceutical drug that is biologically active
2) Nikolakakis & Partheniadis
3) GlobalData

XR-17™ - powerful platform that can increase solubility of insoluble compounds

Active Pharmaceutical Ingredient (API)



WATER INSOLUBLE

XR-17™

Hydrophilic head
Hydrophobic chain

XR-17™ + API



WATER SOLUBLE

XR-17™ increases small molecule solubility and potentially improves safety and efficacy of new formulations

XR-17™ – a validated platform applicable in many therapeutic areas

- Strong, validated safety in cancer indication[1]
- Drug load capacity, enabling high drug delivery capability
- Shorter infusion time[1,2]
- Superior solubility compared with other platforms and technologies, enhances bioavailability of API
- No mandatory or limited need for pre-medication[1]
- Free from alcohol, Cremophor EL, Polysorbate-80 and Human albumin, which can cause numerous side effects

Enable new drugs → Improve existing drugs → 2nd chance for failed drugs

1) Apealea Summary of Product Characteristics. www.ema.europa.eu
2) Paclitaxel 6 mg/ml Summary of Product Characteristics. https://products.mhra.gov.uk

XR-17™ – multiple opportunities in oncology, human and animal health



oasmia

Building a diverse portfolio based on XR-17™ platform technology

Product	Indication	Pre-clinical	Phase I	Phase II	Phase III	Registration / approval	Geography
Human Health Portfolio							
Apealea® / Paclical® (paclitaxel)	Ovarian cancer					Pre-NDA meeting	USA
	Ovarian cancer					✓ ✓	EU / EEA[1]
Technology Platform Portfolio							
Docetaxel micellar	Prostate cancer		Planned				Global
New API	Undisclosed						Global
XR19 (combination)	Assessments in various cancers						Global
Animal Health Portfolio							
Paccal vet (paclitaxel)	Mammary Carcinoma (Canines)					No	US
Doxophos vet (doxorubicin)	Lymphoma (Canines)					No	US

XR-17™ – broad IP protection up to 2036

PROCESS

Protects the manufacturing process for XR-17™

PCT application granted

4 patents granted
In USA, ZAF

Application pending in Eurasia, European Patent Office, AUS, BRA, CAN, CHN, IND, IDN, JPN, MYS, MEX, NZL, KOR, SGP and UKR

WATER-INSOLUBLE

Protects poorly water-soluble APIs[1] in combination with XR-17™

56 patents granted
across Eurasia, European Patent Office, AUS, CAN, CHN, HKG, JPN, KOR, MEX, MYS, NZL, UKR, USA, ZAF

SPC applied for in the EU, pending
(5-year extension)

ANTICANCER COMPOSITIONS

Protects XR-17™ in combination with chemotherapeutic agents

6 patents granted
In USA, FRA, GBR, DEU, CHN and HKG

1) active pharmaceutical ingredient
PCT, Patent Cooperation Treaty
SPC, Supplementary Protection Certificates

Apealea® – offering improved treatment options

apealea®
paclitaxel (micellar)

Approved in EU/EEA for treatment of first relapse ovarian cancer[1] and in Russia for first line and relapsed ovarian cancer[2]

Current standard of care in Ovarian cancer is carboplatin + paclitaxel

Subset of patients cannot tolerate solvent-based paclitaxel

Apealea® is an IV injectable formulation using XR-17™ which facilitates solubility of paclitaxel

elevar therapeutics

1) Apealea® Summary of Product Characteristics. www.ema.europa.eu
2) Paclical® Instructions for medical use. https://grls.rosminzdrav.ru

oasmia

The growing taxane market for ovarian and other cancers

The 2018 global injectable taxane market was valued at $2.18B
The market is expected to grow $4.56B by the end of 2025 (CAGR 11% 2019 – 2025)

Taxol®

- Paclitaxel – cremophor EL
- Ovarian, breast, lung and Kaposi Sarcoma cancers
- Best selling drug of all time with annual sales of $1.6B prior to patent expiration (2000)

Taxotere®

- Docetaxel – polysorbate 80
- Breast, lung, prostate and head & neck cancers
- Peak sales $3B (2010)
- ~$170M (2019)

Abraxane®

- Paclitaxel – albumin bound
- Breast, lung and pancreatic cancers
- $1.35B (2019)

Jevtana®

- Cabazitaxel – polysorbate 80
- Prostate cancer
- ~$480M (2019)

Apealea® is the only non-cremophor drug approved for use in advanced stage ovarian cancer in the EU

Apealea® - multiple benefits compared to the competition

Company	oasmia	Bristol Myers Squibb	Celgene	LUYE PHARMA	samyang Biopharm
	apealea® paclitaxel (micellar)	Taxol®	Abraxane® nanoparticle albumin bound paclitaxel	Lipusu®	Genexol-PM® Korea
Indication	Ovarian Cancer	Ovarian Cancer Breast Cancer NSCLC	Breast Cancer	Ovarian Cancer Breast Cancer NSCLC	Ovarian Cancer Breast Cancer NSCLC
Infusion Solution	Micellar Solution	Emulsion	Colloidal Suspension	Liposome	Micellar Solution
Particle Size	25nm	10-22nm	130nm	400nm	~25nm
Excipient	XR-17™	Cremophor EL	Human Albumin	Lecithin/Cholesterol	PEG-PDLLA
Dose	250mg/m^2	175mg/m^2	260mg/m^2	175mg/m^2	260mg/m^2
Ratio (Excipient : API)	1.3:1.0	88.0:1.0	9.0:1.0	-	5.0:1.0
Infusion Time	1h	3h	<1h	3h	0.5h
Pre-medication	Not mandatory	Yes	No	Yes	No
Hypersensitivity	No	Yes	No	Yes	No

Apealea® – meeting unmet medical needs in selected ovarian cancer

OVARIAN CANCER INCIDENCE[1]



295,000 women diagnosed in 2018 – 8th most common cancer in women[1]

70% of women have a relapse three years after diagnosis[2]

Platinum analogs used alone or in combination with paclitaxel are the most used therapeutic agents[3]

*) China, Japan and South Korea

1) Global Cancer Observatory
2) Springerplus. 2016; 5(1): 1197. Published online 2016 Jul 28. doi: 10.1186/s40064-016-2660-0
3) ESMO guidelines: Annals of Oncology 30: 672–705, 2019 doi:10.1093/annonc/mdz062 Published

oasmia

Apealea® – global partnership worth up to $698m + royalties

Agreement with US-based Elevar Therapeutics, subsidiary of South Korea's HLB

$20M Upfront payment

% Double digit royalties on global Apealea® sales

$678M Milestones based on regulatory and sales achievements

✓ Oasmia retains sole control over development of XR-17™ in other APIs

Named patient program initiated with Tanner Pharma Group ex US Elevar considering European partners for commercial sales



Docetaxel micellar in clinical development

- Prostate cancer is a leading cause of cancer death in men worldwide
- Widely approved for wide range of solid malignancies and standard of care for advanced prostate cancer
- Docetaxel micellar uses XR-17™, enabling IV administration of water-insoluble compounds without traditional solubility enhancers
- Being investigated for advanced prostate cancer in a Phase I clinical trial with the Swiss Group for Clinical Cancer Research (SAKK)

Why invest in Oasmia?

Multiple potential near and mid-term catalysts & value drivers…

Near-term (12 months)

- Elevar partnering for Apealea® in Europe, China
- Apealea® royalties
- Docetaxel micellar Phase 1 initiation
- Review of Animal Health assets
- XR-17™ partnering
- M&A opportunities
- XR-19 value assessment

Mid-term (12-24 months)

- Apealea® milestones and royalties
- Docetaxel micellar Phase 1 results / potential Phase 2 initiation
- Potential initiation of XR-19 program
- Strengthening of balance sheet through existing cost control measures
- M&A and in-licensing opportunities to build critical mass

Sustaining Oasmia's transformation since CEO appointment

- **Strategic**
  - Working progress on
    - Achieving Elevar deal milestones
    - Creating revenue opportunities for the animal health business and for XR-17™
- **Human Resources**
  - Reviewed and implemented right-sizing of the organization
  - Strengthened management team with C level hires

- **Operational**
  - Articulated and implemented docetaxel micellar clinical development plan incl. a collaborative agreement with SAKK
  - Preclinical work with new API and XR-19 on-going
  - Starting up a Patient Access Program in the EU through Elevar
- **Financials**
  - Implemented cost savings of SEK 100m and burn rate of less than SEK 10m/month
  - Resolved large corporate liabilities
- **Investor Relations**
  - Broadened research coverage

Opportunity to build long-term, profitable specialty pharma company through
in-house R&D/M&A/and in-licensing of late stage assets

Solid foundations in place to build a profitable speciality pharma company

Realising our vision for success

Platform to build a Sweden-based cash-flow positive specialty pharma leader

Well placed for M&A and licensing collaborations